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ABSTRACT 
Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system 
causing axonal demyelination and leads to significant disabilities. MS affects mainly young adults and 
incidence of disease in Sweden is around 600 new cases/year. Genetic factors together with 
lifestyle/environmental influences contribute to MS pathogenesis, though their functional roles and 
mechanisms leading to disease are incompletely understood and current treatments exhibit modest 
effect and harmful side effects. Identification of risk genes and elucidation of molecular mechanisms 
will shed light on disease pathophysiology. 
In this thesis, we used experimental autoimmune encephalomyelitis (EAE), an animal model 
mimicking clinical and pathological features of MS, to genetically dissect and study the role of 
antibodies (Abs) against myelin and neuronal antigens. Additionally, we attempted to pinpoint risk 
genes and investigate molecular pathways controlling antibody response and EAE. 
Following a hypothesis-free approach, we identified that Ab response against myelin oligodendrocyte 
glycoprotein (MOG) was under polygenic control and antigen-presenting lectin-like (APLEC) genes, 
encoding C-type lectin receptors (CLRs), were the major regulators. Likewise, Ab response against 
neurofascin was also genetically regulated and correlated with EAE severity, encouraging further 
attempts to study MS genetics in relation to severity as well. Moreover, genetic regions controlling Ab 
response overlapped with EAE-regulating regions, implying common molecular pathways, and Ab 
titers correlated with disease susceptibility and severity implicating Abs in disease pathogenesis. We 
identified differential genetic regulation of Th2-related IgG1 isotype versus Th1-related IgG2b 
isotype. Moreover, the protective effect of IgG1/IgG2b ratio that we observed during EAE may have a 
potential significance in relation to therapeutic agents that promote Th2 predominance. 
Functional studies were performed on congenic lines to elucidate the role of CLRs, able to sense also 
endogenous alarm signals, in EAE pathogenesis. We identified that macrophage C-type lectin (Mcl) 
and macrophage inducible C-type lectin (Mincle) receptors, mainly expressed on myeloid cells, are 
essential for the amplification of the inflammatory response in the CNS and are able to modulate EAE 
by skewing the immune response towards Th17 pathway. Unraveling molecular mechanisms 
underlying CLRs signaling is particularly important as these receptors may serve as novel therapeutic 
targets. 
Combining genetic and immunological studies on experimental models is a promising approach that 
gives insight in disease mechanisms and facilitates the development of effective prognostic, diagnostic 
or therapeutic tools/agents. 
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1 INTRODUCTION 
1.1 COMPLEX DISEASES 
The revolution in medical genetics came almost 35 years ago when genetic mapping was 
applied to identify genes responsible for simple Mendelian diseases 1. However, most of the 
diseases do not follow simple Mendelian monogenic inheritance patterns. These are 
polygenic diseases where multiple genes, each having a small and/or interactive role, 
contribute to disease susceptibility 2. These diseases are also characterized by complexity, 
meaning that nutritional, geographical, infectious and other environmental influences will add 
to disease risk or interact with gene variants, so-called gene-environment interactions. The 
complexity of these diseases applies also in their genetic dissection, where predisposing 
genes might have a small or a moderate effect to the overall risk, same genes might result in 
different phenotypes or disease risk may be influenced by post-genomic modifications or 
epigenetic changes 3.  
The underlying susceptibility of an individual to develop disease may be defined by the 
liability threshold model (Figure 1) 4,5. According to the threshold model hypothesis, the 
members of a population have a normal (Gaussian) distribution of genetic liability for a 
particular disease and a threshold value exists. Several environmental and stochastic factors 
and epigenetic interactions contribute to the disease, each having small effects. The effects 
add up and once the cumulative effects of the factors pass the threshold, an individual 
becomes affected. 
 
 
 
Individuals*
Disease*
Genes*
Epigene1c*eﬀects*
Environmental*factors*
Threshold*
Unknown*factors*
Figure 1. The threshold 
model for susceptibility to 
complex disease. An 
individual will develop a 
complex disease once the 
accumulation of predisposing 
factors (e.g. genetic, 
epigenetic, environmental 
and unknown) and the 
interaction between them will 
exceed the threshold level for 
total risk. 
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Examples of common complex immune-mediated diseases include type 1 diabetes (T1D), 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Crohn’s disease and multiple 
sclerosis (MS). In this thesis, we try to identify and functionally characterize gene variants 
contributing to MS by using a translational research approach. Great advances in the field of 
genetics have given insight in disease pathogenesis, however resolving the complexity that 
underlies the susceptibility of such a polygenic human disorder remains a great challenge.  
1.2 MULTIPLE SCLEROSIS 
MS is a chronic inflammatory disease where the first comprehensive clinical and pathological 
description was made by neurologist Jean-Martin Charcot in 1868. MS affects the central 
nervous system (CNS) i.e. the brain and spinal cord causing neuronal axon demyelination and 
subsequent axon loss. MS is a common disorder among young adults in the Western world 
(around 2.5 million people are affected worldwide 6). Disease prevalence in Sweden is 
approximately 0.19% and incidence is around 600 new cases/year 7. The disease usually 
starts in early adulthood, between 20 and 40 years of age, and preferentially affects women 
with a ratio of almost 2.35:1 man. MS patients not only have lower life expectancy but also 
their quality of life is markedly reduced as a result of their significant disabilities. To date and 
in line with the complexity of MS, a long series of gene variants and lifestyle/environmental 
factors have been associated to increased risk for disease, though their precise functional roles 
are not clear. Furthermore, treatments available for MS are fairly effective, however comprise 
potential risks. 
1.2.1 Clinical features and course 
MS is characterized by demyelination, inflammatory cell infiltration and neurodegeneration 8. 
Axonal demyelination leads to defect saltatory conduction of action potentials resulting in 
various clinical symptoms and signs that reflect the functional anatomy of affected sites. MS 
patients may comprise a variety of clinical symptoms such as balance and vision disturbance, 
bowel and bladder function impairment, loss of sensation, cognitive impairment, fatigue and 
motor disturbances 9. A common method of evaluating the functional status of MS patients is 
the expanded disability status scale (EDSS) 10. EDSS is based on quantification of 
neurological signs of different functional groups i.e. pyramidal, sensory, cerebellar, brain 
stem, bowel and bladder, visual and cerebral or mental. 
Besides dissemination in space, another key characteristic of MS is dissemination in time, i.e. 
appearing episodically over time 11,12. Clinically isolated syndrome (CIS) is characterized the 
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first clinical presentation of a demyelinated disease that could potentially be MS but still does 
not fulfill the criteria of dissemination in time. The majority of MS patients appear with the 
relapsing remitting subtype of MS (RRMS) characterized by acute clinical attacks of 
demyelination followed by periods of remission with complete or partial recovery (Figure 2).  
Most of RRMS patients will enter the secondary progressive phase of MS (SPMS) where 
gradual worsening of the symptoms takes place without remissions and neurological 
disabilities are accumulated (Figure 2). Some MS patients experience continuous worsening 
of their symptoms upon disease onset featuring primary progressive form of MS (PPMS).   
 
Figure 2. Multiple sclerosis clinical course. The spectrum of clinical multiple sclerosis (MS) is 
variable, ranging from a monotonically progressive course (PPMS) to relapsing remitting MS 
(RRMS) with prominent inflammation, possibly preceded by a clinically isolated syndrome (CIS) 
years before RRMS sets in. A majority of RRMS patients will later develop a secondary progressive 
disease (SPMS). Figure adapted after 13. 
1.2.2 Immunopathology 
The pathologic hallmark of MS is demyelinated plaques within the CNS accompanied by 
inflammation, gliosis, oligodendrocyte (OGD) death, neurodegeneration, axonal loss and 
remyelination 8,14. Damage in the blood brain barrier (BBB) enables the infiltration of 
inflammatory cells, and macrophages containing myelin debris, CD8 and CD4 T cells, B 
cells, plasma cells, antibodies (Abs) and complement have been observed in active MS 
lesions. Early active MS lesions are characterized by a profound pathologic heterogeneity 
suggesting that diverse mechanisms may account for MS pathogenesis in different disease 
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subgroups. Lucchinetti et al have categorized MS lesions into four distinct patterns according 
to demyelination and pathological features of the analyzed MS brains 15,16: 
• Pattern I (15%): perivascular demyelination with activated macrophages, microglia 
and T cells, and extensive remyelination. 
• Pattern II (58%): similar to Pattern I. Additional deposition of immunoglobulin (Ig) 
and complement at sites of active myelin destruction. 
• Pattern III (26%): Inflammatory T cells and macrophages with distal OGD apoptosis, 
preferential loss of the periaxonal myelin components and limited remyelination. 
• Pattern IV (1%): Similar to Pattern I with primary OGD injury, extensive OGD 
degeneration and limited remyelination. 
Even though MS has been considered a white matter disease, demyelinated plaques have 
been observed also in the gray matter 17 and they may reflect the pathologic substrate of 
cognitive impairments that MS patients might comprise 18. Besides the focal demyelinated 
lesions, MS brains, mainly in the progressive forms of disease, are characterized by a 
diffuse injury of the normal-appearing-white matter illustrated by perivascular and 
parenchymal inflammatory infiltrates 19.  
Axonal loss may be due to inflammatory but also non-inflammatory factors such as loss of 
trophic support by glia cells 20, and over time the pathological changes become dominated 
by neurodegeneration that leads to progressive accumulation of disabilities 9. 
Remyelination varies among patients and is characterized by thinly myelinated axons 
depending on the availability of OGD precursor cells and the balance between pro- and 
anti-inflammatory processes 15,21. 
1.2.3 Diagnosis 
Diagnostic criteria for MS include both clinical and paraclinical evaluations in order to assess 
the main features of disease i.e. dissemination of lesions in space and time 22. The 
MacDonald criteria, based on clinical, radiologic and laboratory assessments, are the most 
commonly used criteria to diagnose and differential diagnose MS. Magnetic resonance 
imaging (MRI) discriminates active from older demyelinated plaques and identifies lesions 
reflecting BBB damage and brain atrophy 23. Around 90% of MS patients comprise IgG 
oligoclonal bands (OCB) in cerebrospinal fluid (CSF) that are not detectable in the serum, 
thereby providing a powerful diagnostic tool for MS 24. Lastly, delayed nerve evoked 
potentials are also useful in identifying clinically silent lesions in MS patients 25.  
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1.2.4 Treatment 
Despite the significant advances occuring in the last 20 years in understanding MS 
pathogenesis, there is still no fully effective treatment available for the disease, and all 
approved therapeutics (Table 1) aim to aleviate symptoms or to prevent rather than repair 
tissue damage.  
Until 1993, when interferon β (IFNβ) was first approved to treat MS relapses 26, 
exacerbations of disease were symptomatically treated only with high doses of intravenous 
methylprednisolone 27. Interferons are not only anti-viral drugs but also endogenous 
cytokines with the capacity to immunologically modulate cellular signaling, gene 
transcription and innate and adaptive immunity 28. IFNβ treatment is complicated by 
frequent development of neutralising antibodies resulting in lower drug efficacy 29. Another 
drug for MS is glatiramer acetate (GA) that is believed to induce tolerance or anergy of 
myelin-reactive lymphocytes 30. IFNβ and GA are first-line agents for MS patiens and give 
approximately 30% reduction in annual relapse rate 31. However, none of these have 
emerged as superior treatments given the relatively low efficacy and the variable adverse 
effects they may cause. 
Much better efficacy in MS treatment was achieved with the approval of natalizumab to 
treat MS patients in 2003. Natalizumab is a humanized monoclonal antibody (mAb) that 
targets α4-integrin in leucocytes leading to reduced cell infiltration into the CNS through 
the BBB 32. Despite its high efficacy (it is the most effective treatment for MS to date), 
natalizumab has a major side effect which is the development of progressive multifocal 
leukoencephalopathy (PML), a rare, but often fatal opportunistic infection that is caused by 
polyoma JC virus (JCV) 33 34. That led to the introduction of measurement of JCV Abs, that 
predict individuals at high PML risk, as a routine in clinical practice. A recently (2009) 
approved drug for MS with the advantage of being orally administered is fingolimod 35, and 
with natalizumab represent the second-line agents for MS treatment. Fingolimod 
downregulates S1P receptor on leukocytes resulting in T cell trapping in the lymph nodes 
(LN). Alemtuzumab, a leucocyte-depleting mAb was recently approved as a second or third 
line treatment, however, connected to frequent development of other autoimmune diseases 
36. 
Two more immunomodulatory agents have been recently approved as first-line treatment 
for disease, teriflunomide and dimethyl fumarate, and few more such as ocrelizumab 
(CD20+ B cell-depleted Ab), laquinimod, daclizumab and atumumab are under advanced 
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clinical studies to verify their efficacy and safety 31. Despite the wide range of therapeutics 
for RRMS, there are no available effective treatments for SPMS and PPMS. 
Table 1. Efficacy ranking of approved therapies for multiple sclerosis. Table adapted after 31. 
Drug Era of development Mechanism of action 
Most effective   
Natalizumab Second Monoclonal antibody 
against integrin-α4 in 
leukocytes 
Highly effective   
Fingolimod Second Sphingosine S1P receptor 
modulator 
Dimethyl Fumarate Third Immunomodulator 
Alemtuzumab Second or third Leucocyte-depleting 
monoclonal antibody 
Moderately effective   
IFNβ First Immunomodulator 
Glatiramer Acetate First Immunomodulator 
Teriflunomide Third Pyrimidine synthesis 
inhibitor 
 
1.2.5 Aetiology 
Familial/genetic, twin/adoption and environmental/migration studies have a major 
contribution on our understanding of MS aetiology. MS is considered to be a complex 
disease, where genetic and environmental/lifestyle factors together with epigenetic changes 
and stochastic events contribute to disease pathogenesis (Figure 3).  
 
MS# epigene)c#
environmental#
gene)c#
stochas)c#
Figure 3. Multiple sclerosis risk factors. 
Genetic, environmental/lifestyle factors together 
with epigenetic changes and stochastic events 
contribute to disease pathogenesis.  
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1.2.5.1 Genetic risk factors 
The genetic component of MS has become evident by familial studies of MS aggregation 37. 
Approximately 20% of MS patients have a familial history of the disease, and concordance 
rate in monozygotic twins is higher compared to dizygotic twins. The genes strongest 
associated to MS are the ones encoding human leucocyte antigens (HLAs). The HLA class 
II, HLA-DRB1*15:01, has been associated with increased risk of MS whereas the HLA 
class I, HLA-A*02:01, has been shown to confer protection 38. The contribution of other 
HLA haplotypes, such as DRB1*13:03, DRB1*03:01 and DRB1*08:01, in MS 
pathogenesis has recently been confirmed. Despite the several efforts on non-HLA risk 
gene identification during the last few decades, little progress was made until gene centered 
and genome wide association studies (GWAS) were implemented. The first GWAS 
identified variants in both IL-7R and IL-2RA as heritable risk factors for MS 39. Since the 
first GWAS, in total 14 GWASs have been executed in MS and collectively they have 
identified approximately 110 non-HLA variants to increase risk for MS, though having a 
relatively smaller impact compared to HLA genes 40. Interestingly, the majority of 
identified variants are involved in immune functions providing compelling evidende 
supporting the inflammatory versus neurodegenerative component on disease pathogenesis 
41.  
1.2.5.2 Environmental risk factors 
The relatively modest familial risk, the low concordance rate of MS in monozygotic twins 
42 and the uneven geographical distribution of disease (prevalence is increased with 
distance from the equator) 43 highlight the environmental influences as contributors in 
disease pathogenesis. Migration studies show that adolescents who move between regions 
with diverse disease prevalence acquire the risk of the new geographical area, and argue for 
the great impact of environmental exposures, during childhood and early adolescence, on 
disease susceptibilty 44.  
MS incidence and prevalence increase with the distance from the equator and high 
prevalence areas include Europe, North America, Australia and New Zealand 45. A possible 
explanation for this latitude-dependent gradient of disease is the lower exposure to 
sunlight/ultraviolet radiation (UVR) and the subsequent decreased vitamin D levels 46.  
Other environmental triggers include active and passive smoking, obesity during 
adolescence, night shift work before the age of 20, exposure to organic solvents and 
Epstein-Barr virus (EBV) serology 47. Interestingly, EBV is a common herpes B-cell tropic 
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virus and more than 90% of all individuals worldwide become affected usually during early 
childhood, though only a small percentage of EBV carriers will develop infectious 
mononucleosis (IM). Individuals with IM have a higher risk of developing MS compared to 
both EBV carriers and non-carriers and the latter have an extremely lower risk of MS 
compared to EBV carriers 48. Importantly, the consistent finding that MS patients have 
increased anti-EBNA (EBV nuclear antigen) antibody titers prior to MS onset has led to a 
debate of whether or not EBV is the causal factor for MS development. Though, the 
underlying mechanisms behind viruses and other environmental triggers are still unknown 
and under rigorous investigation 47.  
1.3 EXPERIMENTAL ANIMAL MODELS 
An alternative approach to study human diseases is the use of experimental animal models. 
In the recent years a number of animal models have been developed mainly to elucidate the 
basic biology behind the disease and to monitor the development of new therapeutic 
approaches. The main advantages of the use of animal models is the availability of tissues 
and the relatively unlimited sample size. In genetic studies the use of animals enables the 
development of experimental crosses and genetically identical individuals (inbred and 
congenic strains) and permits the control of environmental influences.  
1.3.1 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
Especially for MS in which the target organ of the disease, the CNS, is not easily accessible 
in humans, the use of an animal model is even more imperative compared to other diseases. 
It was almost a century ago 49, when researchers first attempted to reproduce the 
encephalitogenic effect of rabies vaccination on monkeys, that the whole concept of 
experimental autoimmune encephalomyelitis (EAE) as an animal model for MS initiated. 
Since then EAE has become the most powerful tool to study clinical, neuroimmunological, 
genetic and other aspects of human MS in the laboratory. EAE has been elicited in a wide 
range of species such as mice, rats, rabbits, monkeys and guinea pigs and a number of 
diverse models have been developed with the aim to reproduce different aspects of MS 50. 
Classic EAE can be actively induced by injecting CNS homogenate or a CNS antigen 
together with an adjuvant. The most commonly injecting antigens are myelin proteins or 
peptides e.g. myelin oligodendrocyte glucoprotein (MOG) and myelin proteolipid protein 
(PLP) 51.  The use of mineral oil (Freund’s) as an adjuvant leads to faster induction of 
disease and the addition of heat-inactivated mycobacteria tuberculosis to the adjuvant 
(complete Freund’s adjuvant) or injections of pertussis toxin are necessary in many models 
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to augment or even induce disease 52. The clinical outcome, the CNS pathology and the 
effector cells of the elicited disease depend on the animals’ genetic background and the 
immunization protocol i.e. selected antigen and adjuvant.  
Alternatively, passive EAE can be induced by transfer of myelin specific T cells and results 
in a short monophasic disease with minimal demyelination and rapid recovery 53. Even 
though most of EAE models are induced, spontaneous EAE has been observed in 
transgenic mice over-expressing myelin basic protein (MBP)-specific T cell receptor (TCR) 
54,55. 
In general, EAE has been useful mainly in dissecting immunogenetic, histopathological and 
therapeutic aspects of MS. For example, GA and natalizumab were first developed based on 
their success in treating EAE. Nonetheles, EAE is not MS and there are major differences 
between these two 56. First of all, MS is a spontaneous disease while the majority of EAE 
models are induced. Moreover, EAE, which is studied in inbred animals living under 
controlled laboratory conditions, does not reflect the complexity of human MS. Despite 
these limitations, much of our current knowledge for MS pathogenesis derives from studies 
on EAE and when EAE is used appropriately is a great tool for investigating such a 
complex disease 57.  
1.4 IMMUNOLOGY 
1.4.1 ADAPTIVE IMMUNITY 
1.4.1.1 T cells 
The clinical heterogeneity of MS reflects both the genetics and the complex, multicellular 
pathophysiological processes.  
The similarities between CD4+ T cell mediated EAE and MS 58 and the identification of 
certain major histocompatibility complex (MHC) class II as risk genes for MS 39 promoted 
studies on the potential role of CD4 T cells in disease immunopathogenesis. As 
demyelination is the main characteristic of MS pathology, it has been hypothesized that a 
myelin antigen should be the potential auto-reactive antigen 59. Indeed, T cells from MS 
patients recognize a wide range of myelin proteins including MOG 60, MBP 61 and PLP 62 
among others. However, auto-reactive T cells, although of a different phenotype, are found 
also in healthy individuals 63,64, and there is a controversy on the evidence regarding 
differences in T cell frequency and avidity between the two groups 59. Furthermore, T cells 
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have been shown to recognize non-myelin antigens as well such as aB crystalline 65 and 
contactin-2, which is a neuronal protein 66. It is likely that T cells recognize a diverse and 
extensive array of antigens during MS development, however how and why these T cells 
become abnormally activated towards CNS antigens remains to be elucidated 67.  
Until recently, several data indicated the prominent role of CD4+ Th1 cells, that require IL-
12 for their differentiation and they secrete IFNγ, IL-2 and TNF, in MS pathogenesis. 
Among other findings, MS was exacerbated by IFNγ administration 68, increased MS 
clinical activity correlated with IFNγ and IL-12 expression in the CNS and CSF 69, and 
adoptively transferred Th1 cells could induce EAE 70. The observation that mice deficient 
in IL-12, IFNγ and TNF develop severe EAE 71, while IL-23-deficient mice 72 are 
completely resistant led to the identification of Th17 cells, that need TGFβ, IL-6 and IL-1 
for their differentiation, produce IL-17 and IL-22 and induce GM-CSF and IL-6 synthesis, 
as important cellular mediators in neuroinflammation 58. Increased IL-17 expression has 
been detected in blood and CSF of MS patients as well as in MS brain lesions 73,74. The 
observation that Th17 cells induce more severe EAE compared to Th1 cells and 
neutralization of IL-17 activity could ameliorate EAE 75-78 led to the notion that Th17 cells 
might be the true effector cells of CNS autoimmunity 58. Even though the relative 
contribution and importance of Th17 versus Th1 cells is not clear to date, these T cell 
subsets comprise a preferential distribution in the CNS during EAE suggesting differential 
regulation of neuroinflammation in the brain and spinal cord 79.  
Even though CD4+ T cells contribution in MS and EAE has been extensively studied, 
CD8+ T cells outnumber CD4+ T cells in MS lesions and their numbers correlate with 
axonal damage, a finding that stronlgy suggests their implication in disease 
immunopathogenesis 80. Furthermore, oligoclonal expansion of CD8+ memory T cells have 
been detected in CSF and brain tissue from MS patients 81,82, and adoptively transferred 
CD8+ T cell induced severe EAE in mice 83. Taken together, there is no doubt that both 
CD4+ and CD8+ T cells contribute to disease pathogenesis, although they may have 
distinct roles at different steps.  
1.4.1.2 B cells and autoantibodies 
Even though there is a “T cell centric” approach of MS pathophysiology, the prominent role 
of B cells and autoantibodies has become solid by a wide range of evidence. Intrathecal 
antibody production and CSF IgG OCB are hallmark findings of MS patients 24 and they 
serve as diagnostic and prognostic markers 84. These intrathecal IgG are synthesized by 
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local plasmablasts and plasma cells but their antigenic target is not known to date 85. B cell 
follicle-like aggregates had been detected in the meninges of RRMS and SPMS patients and 
their presence correlated with cortical pathology and more aggressive clinical course 86-88. 
Furthermore, elevated levels of B-cell activating factor (BAFF), the major survival factor 
for B cells and CXCL13, a B-cell chemoattractant chemokine have been detected in MS 
patients 89,90. Taken together the previous observations suggest that CNS in MS patients 
provide a fostering inflammatory milieu for the survival of B cells and Ig-producing plasma 
cells 91. Lucchinetti et al has categorized MS brain lesions into four distinct patterns (for 
detailed description see before “Immunopathology”), and Pattern II lesions are 
characterized by prominent immunoglobulin deposition and complement activation. 
Furthermore, therapeutic plasma exchange, that depletes autoantibodies, has successfully 
treated MS demyelinating attacks and MS patients with pattern II lesions are more likely to 
improve after plasmapheresis 92. The therapeutic effect of rituximab, an anti-CD20 mAb 
that depletes B cells but not antibody producing plasma cells indicates that pro-
inflammatory features of B cells may dominate in many MS patients 93. Additional 
evidence for the fundamental role of B cells in MS are provided by genetic studies where B 
cells showed significant enrichment of genomic regions associated with MS 94 and by 
environmental studies that have indicated the B-cell tropic EBV as a strong risk factor for 
MS 48. 
In addition to antibody production, B cells exert not only pro-inflammatory functions 
through production of cytokines such as IL-6 95 but also have anti-inflammatory features 
through the production of anti-inflammatory cytokines such as IL-10 96 and neurotrophic 
factors such as brain-derived neurotrophic factor (BDNF) 97. Likewise, antibodies may not 
only be damaging through mechanisms such as activation of complement and antibody-
dependent cellular cytotoxicity (ADCC) but have also regulatory roles 98 as indicated by the 
successful intravenous Ig (IVIG) treatment of patients suffering from autoimmune or 
inflammatory diseases 99.  
Anti-MOG auto-antibodies 
The oligoclonal nature of the IgG OCB, found in the majority of MS patients, suggests that 
MS is an antigen-driven disease and identifying the auto-antigen would offer significant 
insight in disease pathogenesis. Despite that several autoantigens have been proposed as 
potential targets in MS, their clinical relevance remains controversial. As MS is a 
demyelinating disease, a substantial amount of studies have focused on CNS myelin-
 12 
specific autoantigens 100 such as MOG 101, MBP 102, PLP 103 and myelin-associated 
glycoprotein (MAG) 104. However, numerous non-myelin antigens have been also identified 
as potential Ab targets including autoantigens of oligodendrocytes (e.g. CNPase, 
transaldolase and transketolase), astrocytes (e.g. potassium channel KIR4.1), cellular ion 
channels (e.g. anoctamin 2), microbial (e.g. viral) and many more 105,106. The recent 
detection of axon-specific autoantibodies such as against neurofascin and contactin has 
contributed in the long list of MS candidate autoantibodies 66,107. Despite the numerous 
studies on the field of MS autoantigens, none were ultimately identified to be MS specific.  
Unlike intracellular antigens such as MBP and PLP, MOG is unique due to its localization 
on the surface of oligodendrocytes and the myelin sheath (Figure 4), thereby available for 
antibody binding 108. Demyelinating MOG autoantibodies were first identified in EAE 30 
years ago 109 and when co-transferred together with MBP-specific CD4+ T cells accelerated 
clinical signs of EAE and induced demyelination 110-113. Moreover, demyelination observed  
  
Figure 4. Distribution of CNS myelin proteins. A neuron with a myelinated axon is depicted. 
Myelin enwraps the axon at intervals called internodes omitting small opening termed nodes of 
Ranvier. Adjacent to the nodes of Ranvier are the paranode and the juxtaparanode. MOG, myelin 
oligodendrocyte glycoprotein; NF186, neurofascin 186; NF155, neurofascin 155; MBP, myelin basic 
protein; MAG, myelin associated glycoprotein; PLP, proteolipid protein. Figure adapted after 114.  
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in these models was associated with immunoglobulin and complement deposition 101,115 
reflecting the immunopathology of Pattern II MS lesions according to Lucchinetti’s 
classification. Notably, myelin injury is not induced by anti-MBP or anti-PLP Abs transfer 
110. 
The identification of the demyelinating nature of anti-MOG Abs in EAE, initiated a 
rigorous research on the evaluation of these Abs in MS, albeit with controversial and 
conflicting results. MS patients were reported to have elevated serum and/or CSF anti-
MOG Ab levels in some studies 116,117, while in other studies no differences in the anti-
MOG Ab titers were detected between MS patients and controls 118,119. The lack of 
reproducibility between the research groups highlighted the necessity of developing 
techniques to selectively detect pathogenic MOG-specific autoantibodies that would 
recognize the native protein as it exists in vivo. For an antibody to be pathogenic it has to 
fulfill several criteria. Among them, the antigenic epitope the antibody recognizes has to be 
expressed at a site within the CNS easily accessible to the antibody, and, at the molecular 
level, the epitope recognized must also be accessible in vivo 120. Until ten years ago, that 
was not the case in the majority of the studies where anti-MOG Abs recognized the 
denatured recombinant MOG. Since then a successful approach to identify potential 
pathogenic MOG-specific autoantibodies in MS has been the use of live MOG-transfected 
cell lines expressing MOG on their surface 121,122. Notably, there is a consensus that anti-
MOG Abs recognizing native MOG are not present in the sera of the vast majority of MS 
patients implying that they are not involved in the primary pathogenic mechanism of MS 
120,123,124. Nonetheless, Abs recognizing native MOG have been detected in a subgroup of 
pediatric-onset demyelinated disorders such as MS, acute disseminated encephalomyelitis 
(ADEM) and CIS, and the presence of Abs correlated with a younger age of disease onset 
125-130. Other CNS diseases where anti-MOG Abs have been detected include neuromyelitis 
optica (NMO), bilateral optic neuritis and anti-NMDA-receptor (NMDAR)-Ab-associated 
encephalitis 131 (Figure 5).  
Despite the controversy in the field of anti-MOG Abs, it is yet to be elucidated whether 
these antibodies have a pathogenic role in demyelination, as indicated by animal studies, or 
whether they are a secondary epiphenomenon to myelin damage 132. 
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Anti-neurofascin auto-antibodies 
There have been laborious attempts to identify and characterize candidate autoantigens in 
MS using different strategies. Using an unbiased proteomics approach two axo-glial 
antigens, neurofascin 107 and contactin 66, were recently recognized as novel targets of the 
autoimmune response in MS. Neurofascin is an adhesion molecule and exists in two 
isoforms: neurofascin 155 (NF155) that is expressed by oligodendrocytes and located at the 
paranodal axo-glial junction and neurofascin 186 (NF186), a neuronal protein located at the 
node of Ranvier (Figure 4). Both neurofascin isoforms contribute to the voltage-gated 
potassium and sodium channels clustering.  
Mathey et al detected Abs against neurofascin approximately in one-third of MS patients, 
and in a T-cell adoptive transfer model of EAE neurofascin-specific Abs exacerbated EAE 
associated with increased axonal injury caused by the antibody binding to the node of 
Ranvier 107. Anti-neurofascin Abs had also the capacity to impair neuronal transmission in 
vitro. Thus, these novel mechanisms of axonal injury observed in EAE might contribute to 
axonal damage in MS patients as well. Since then, anti-neurofascin Abs have been detected 
in patients with demyelinated disorders of the CNS and/or peripheral nervous system (PNS) 
such as chronic inflammatory demyelinating polyneuropathy 133,134, chronic inflammatory 
demyelinating polyradiculoneuropathy 135 and Guillain-Barre syndrome 136.  
Contactin exists also in two isoforms: contactin-1 that is located at the paranodes and 
contactin 2, expressed by both neurons and glial cells and is localized in the juxtaparanodes 
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(Figure 4).  Derfuss et al found that contactin-2 was recognized by both autoantibodies and 
Th1/Th17 cells in MS patients 137. Additionally, adoptive transfer of contactin-2-specific T 
cells induced inflammation in the rodents’ brain preferentially localized in the gray matter 
of the cortex and spinal cord. These observations paved the way for research on antibody-
mediated cortical demyelination. 
1.4.2 INNATE IMMUNITY 
1.4.2.1 Antigen presenting cells (APCs)  
APCs are involved in multiple stages during MS and EAE immunopathophysiology and 
comprise a wide range of functions from antigen uptake and presentation to T cells to 
cytokines secretion that drives T cell differentiation 138.  
Perivascular macrophages (PVM) are able to express MHCII and it is now clear that their 
strategic location enables them to initiate and maintain neuroinflammation 139. During MS 
and EAE, PVM up-regulate MHCII and co-stimulatory molecules such as CD80, CD86 and 
CD40 and their activation is mediated by IFNγ and TNF 139. In addition, elimination of 
PVM suppresses clinical signs of EAE 140,141. The finding that depletion of microglia in 
EAE was followed by reduced disease onset, progression and demyelination highlights the 
importance of microglia in EAE and MS pathogenesis 142. Due to the abundance of 
microglia within the CNS, they are a powerful source of pro-inflammatory cytokines and 
chemokines important for maintenance of immune response. Phagocytosis of myelin by 
microglia and macrophages in vitro triggers pro-inflammatory cytokines, such as IL-6, IL-1 
and TNF, and NO release 143-145. It has also been shown that during EAE, IL-23 expression 
in CNS CD11b+ cells (macrophages, microglia and DCs) peaks early in disease, suggesting 
a critical role of these cell subsets during initiation of CNS inflammation prior to T cell 
infiltration 146. Likewise, increased IL-23 and iNOs has been detected in 
microglia/macrophages of active MS lesions 147,148. MS plaques have also been 
characterized by the presence of chemoattractant proteins secreted by microglia and 
macrophages, thus contributing in leukocyte infiltration into the CNS and enhance 
neuroinflammation 149. 
The importance of DCs in MS has become evident by studies showing the presence of 
immature and mature DCs in the meninges and parenchyma of MS patients 150. 
Furthermore, DCs contained myelin antigen deriving from demyelinating lesions has been 
observed in the cervical LNs of MS patients and monkeys affected with EAE implying that 
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DCs are able to process and present endogenous myelin 151,152. The prominent role of DCs 
in promoting CNS autoimmune pathology was shown by adoptive transfer EAE 
experiments where CD11c+ DCs were the only APCs required for disease initiation and 
their numbers were correlated with disease severity 153.  
1.4.2.2 C-type lectin receptors (CLRs) 
A growing number of studies highlight the importance of innate sensors in MS 
pathogenesis 154. Evidence suggests that recognition of pathogen-associated molecular 
patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs) by altered 
pathogen recognition receptors (PRRs) might be key events during disease development 155. 
PRRs, mainly expressed on myeloid cells, consist of four main categories: Toll-like 
receptors (TLR), Nod-like receptors (NLRs), RIG-I like receptors (RLR) and C-type lectin 
receptors (CLRs) 156.  
CLRs are either transmembrane or soluble proteins characterized by a carbohydrate 
recognition domain (CRD) that is highly conserved among species 157 and has a calcium-
binding pocket essential for carbohydrate binding. The CLR family now includes receptors 
that have domains homologous to CRD that do not necessarily bind carbohydrates or 
calcium 158.  
Dcir1, Dcir2, Dcir3, Dcir4 and Dcar1 receptors 
Dendritic cell immunoreceptor 1 (Dcir1), Dcir2, Dcir3, Dcir4 and dendritic cell 
immunoactivating receptor 1 (Dcar1) are highly conserved among species and mainly 
expressed in neutrophils and APCs 158. CLRs consist of a CRD, a transmembrane region 
and a short cytoplasmic tail. The cytoplasmic tail of Dcir1-4 receptors contains an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) that upon ligand binding becomes 
phosphorylated and regulates immune signaling via recruitment of SHP1 or SHP2 
phospatases (Figure 5) 159. On the other hand, Dcar1 is functionally associated with 
immunoreceptor tyrosine-based activating motif (ITAM)-bearing Fc receptor-γ (FcRγ) 
chain and signals through spleen tyrosine kinase (Syk) (Figure 6) 158,160. The ITAM versus 
ITIM dichotomy has been useful in understanding the signaling of immunoreceptors but 
does not necessarily indicate activating or inhibitory outcomes 161. Functional studies have 
made clear that CLRs serve as PRRs and upon activation they initiate a signaling cascade 
resulting in shaping innate and adaptive immune mechanisms, although their natural 
ligands have not yet been elucidated.  
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Figure 6. Schematic representation of signal transduction pathways of Dcir and Dcar1. 
Activation of Dcir leads to phosphorylation of its ITIM and SHP1 or SHP2 recruitment that in turn 
induces the activation of an unidentified signalling pathway leading to production of 
immunoregulatory cytokines. Activation of Dcar1 leads to SYK recruitment to the phosphorylated 
ITAM of the paired signaling adaptor FcRγ and induces a signaling cascade through the Card9-Bcl10-
Malt1 complex. NFκB-driven transcription results in the production of immunoregulatory cytokines. 
FCRγ, Fc receptor-γ; Syk, phosphotyrosine kinase; PKCδ, protein kinase C-δ; ΙΤΑΜ, 
immunoreceptor tyrosine-based activation motif; ΙΤΙΜ, immunoreceptor tyrosine-based inhibitory 
motif; NFκB, Nuclear factor-κB. Figure adapted after 158,160. 
 
Dcir receptors have been shown to be important in a number of autoimmune diseases 
(Table 2). A recent publication assessed the impact of Dcir2 in the initiation and 
progression of EAE 162. They showed that Dcir2 Knockout (KO) mice displayed more 
severe disease and had increased anti-MOG35-55 IgG titers compared to wild type (WT) 
mice. Dcir2 KO mice also exhibited higher production of IFNγ and IL-17 and increased 
frequency of Th1 and Th17 cells. Interestingly, Dcir1 KO mice were more severely sick 
during collagen-induced arthritis (CIA) and they displayed higher anti-collagen type II 
(CII) IgG1 Abs compared to WT 163. Lack of Dcir1 predisposed aged Dcir1 KO mice to 
develop spontaneous sialadenitis and enthesitis followed by increased IgG and IgM Ab 
levels, suggesting a protective role of the receptor. On the contrary, the pathogenic role of 
Dcir1 was demonstrated by studies showing that Dcir1 was essential for the development of 
experimental cerebral malaria 164. Evidently, Dcir may exert both pathogenic and regulatory 
functions. Human DCIR polymorphisms have been associated with RA susceptibility and 
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primary Sjögren’s syndrome in Swedish and Asian populations 165-167. BDCA2, the human 
homologous to Dcar1 receptor, has been shown to exert regulatory functions during SLE by 
inhibiting type I IFN production 168 and a recent study suggested that lack of surface 
expression of BDCA2 receptor may be one of the genetic pathophysiological features in 
amyotrophic lateral sclerosis (ALS) 169. 
Mcl and Mincle receptors 
Macrophage C-type lectin (Mcl) and macrophage inducible C-type lectin (Mincle) are 
transmembrane proteins containing a short cytoplasmic tail, a transmembrane domain, an 
extracellular region and a single CRD 170. Mcl and Mincle genes have been mapped to a 
cluster on rat chromosome 4, on mouse chromosome 6 and on human chromosome 12p13 
171,172. 
Mcl and Mincle are mainly expressed on myeloid cells such as macrophages and 
neutrophils, DCs, monocytes, but their expression has also been observed in B cells and T 
cells and Mincle has been detected in neurons and endothelial cells as well 160-162. Mcl has 
been shown to be a monocyte/macrophage endocytic receptor 173,174 and Mincle senses 
fungi and mycobacteria. It has been shown that both Mcl and Mincle are essential receptors 
for the recognition of mycobacterial glycolipid trehalose dimycolate (TDM) 175,176, a known 
innate immune stimulus that possesses strong adjuvant activity.  Yamasaki et al showed 
that Mincle is also a macrophage sensor for damaged cells by recognizing a self 
ribonucleoprotein SAP130 released from dead cells and promotes inflammatory cell 
infiltration into the damaged tissue 177.  
Mincle is associated with an ITAM-bearing FcRγ through a positively charged amino acid 
in its transmembrane region 177. PAMPs or DAMPs recognition leads to ITAM 
phosphorylation and Syk recruitment that induces Bcl10-Malt1-Card9 signaling cascade 
resulting in NF-κB activation and induction of inflammatory cytokines such as TNF, IL-6, 
CXCL1 and CXCL2 (Figure 7) 176-178.  
Lobato et al showed that Mcl interacts with FcRγ in an indirect way, as lack of a positively 
charged amino residue in Mcl transmembrane domain renders it incapable of directly 
associating with FcRγ 179. They further showed that Mcl interaction with FcRγ requires the 
formation of Mcl-Mincle heterodimers and that co-expression of Mcl and Mincle led to a 
dramatic synergistic increase of anti-Mincle bead phagocytosis 180. On the other hand, 
Miyake et al observed a Mincle-independent Mcl-FcRγ co-immunoprecipitation attributed 
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to the hydrophilic nature of threonine 38 that corresponds to the positively charged arginine 
of Mincle at this site 181. The previous findings do not necessarily contradict each other, 
however crystal structure analysis of Mcl-Mincle heterodimers will hopefully shed more 
light on Mcl signaling. Subsequently, Miyake et al observed that Mcl positively facilitates 
both Mincle expression and its signaling 182. In addition to this finding, Zhao et al have 
shown that Mcl serves as a molecular sensor of TDM leading to Mincle expression and that 
depends on NF-κB pathway activation (Figure 7) 183. Whether formation of heterodimers 
between Mcl and Mincle expand ligand specificity or confer complementary functions to a 
single receptor 184 remains to be investigated in future studies. 
  
Figure 7. Schematic representation of signal transduction pathways of Mcl and Mincle. 
Activation of Mcl and Mincle leads to SYK recruitment to the phosphorylated ITAM of the paired 
signaling adaptor FcRγ and induces a signaling cascade through the Card9-Bcl10-Malt1 complex. 
NFκB-driven transcription results in the production of immunoregulatory cytokines and chemokines. 
FCRγ, Fc receptor-γ; Syk, phosphotyrosine kinase; PKCδ, protein kinase C-δ; ΙΤΑΜ, 
immunoreceptor tyrosine-based activation motif; TLR, Toll-like receptor; TDM, trehalose dimycolate; 
NFκB, Nuclear factor-κB. Figure adapted after 160,185,186.  
 
Beyond fungal and mycobacterial infections, Mcl and Mincle have been implicated in a 
number of other CNS diseases, including EAE (Table 2). Miyake et al have suggested that 
Mcl but not Mincle has a prominent role during EAE development 181. They observed that 
Mcl KO mice were almost completely protected against MOG-EAE whereas Mincle KO 
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Table 2. Summary of data on C-type lectin receptors and their genes involvement in 
autoimmune, inflammatory or CNS diseases.  
Gene Role in disease 
Dcir1 Dcir1 KO mice are more severely sick during CIA compared to 
WT 163.  
 Aged Dcir1 KO mice are predisposed to develop sialadenitis 
and enthesitis 163. 
Dcir2 Dcir2 KO mice are more severely sick during EAE compared 
to WT 162. 
DCIR (Dcir1-2 
human orthologue) 
Association to RA and primary Sjögren’s syndrome 166,167. 
BDCA2 (Dcar1 
human orhtologue) 
Potential implication in amyotrophic lateral sclerosis 169.  
 BDCA2 receptor has regulatory function in SLE 168. 
Mcl Mcl KO mice are protected during MOG peptide-EAE 
compared to WT 181. 
Mincle Mincle KO mice are partially protected during MOG peptide-
EAE compared to WT 181. 
 Mincle KO mice showed better outcome after ischemic stroke 
compared to WT 187. Mincle, SAP130 and Syk levels are up-
regulated after cerebral ischemia in mice. Mincle inhibition, by 
piceatannol, rescued cerebral ischemic damage 188.  
 Mincle KO mice are less severely sick during experimental 
autoimmune uveitis 189. 
 Mincle, Syk and SAP130 expression is increased after 
subarachnoid hemorrhage 190. 
 Mincle receptor, SAP130 and Syk levels are elevated in 
patients with TBI 191. 
 Mincle KO mice are protected against autoimmune hepatitis 192. 
 
mice exhibited a partial protection after MOG peptide immunization compared to WT mice. 
In the CNS, it has been shown that Mincle plays a pivotal role in the pathogenesis of 
cerebral ischemia, subarachnoid ischemia and traumatic brain injury (TBI) both in animal 
models and humans. Specifically, Mincle KO mice showed a better disease outcome after 
stroke induction and the absence of Mincle conferred protection to neurons 187. In addition, 
protein expression levels of Mincle, its ligand SAP130 and the downstream molecule Syk 
were upregulated after cerebral ischemia in mice. Moreover, up-regulation of both Mincle 
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and SAP130 followed similar patterns over time implying that SAP130 is the primary 
ligand of Mincle in this context 188. In the same study, they also showed that Mincle is 
expressed in immune cells as well as in neuronal and endothelial cells in ischemic brains of 
both mice and humans. Mincle and SAP130 levels were elevated in the CSF of patients 
with TBI as well as Mincle and Syk protein levels were higher in injured brain tissue 
compared to controls 191.  
Lastly, MALT1 and BCL10, the downstream molecules that are induced after Mcl and/or 
Mincle activation, were found to be strongly associated to human MS in GWAS 41,193. 
Though, how Mcl and Mincle receptors or the signaling pathway they are involved in, 
contribute to disease pathogenesis remains to be investigated.  
1.4.3 DISEASE MOLECULAR MECHANISMS 
Although the primary trigger of MS remains unknown, potential MS etiological mechanisms 
include autoimmune, infectious and degenerative causes with a focus on the immune 
responses 194. Upon encountering an environmental stimulus e.g. an infectious agent, 
genetically susceptible individuals may respond with an autoimmune attack of CNS myelin 
based on molecular mimicry mechanisms between infectious and myelin antigens 195. If this 
response becomes autonomous it may lead to epitope spreading to other CNS antigens 
resulting in a chronic recurrent condition such as MS 195,196.  
Molecular mimicry is the activation of auto-reactive cells by cross-reactivity between self 
antigens and foreign antigens 197. During infections, cross-reactivity of potentially auto-
reactive T cells with infectious agents may lead to T cell activation and infiltration into the 
brain where they can attack CNS antigens. Studies have shown that EBV-specific CD4+ T 
cells and human herpes virus (HHV)-6 isolated from MS patients’ CSF and blood 
respectively, cross-react with MBP 198,199. Olson et al directly demonstrated that molecular 
mimicry did initiate virus-induced demyelination in the Theiler’s murine encephalomyelitis 
virus (TMEV) model of MS 200-202. They showed that demyelination was initiated by 
Theiler’s virus-specific CD4+ T cells and secondary release of sequestered auto-antigens led 
to self-reactive T cell activation and damage of multiple myelin epitopes, such as PLP and 
MOG. Hence epitope spreading mechanisms sustained and enhanced disease progression.  
Epitope spreading is the process where epitopes non-cross-reactive with the inducing antigen 
become major targets of an ongoing immune response 203. Response may be directed against 
different regions of the same protein (intramolecular epitope spreading) or a distinct protein 
(intermolecular epitope spreading). Even though the verification of epitope spreading as a 
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potential mechanism in MS is not easy because the initial antigen is not known, there are 
some evidence that the phenomenon occurs in MS. Tuohy et al followed patients with 
isolated monosymptomatic demyelinating syndrome (IMDS) over the years and when 
patients progressed to clinically definite MS he detected T-cell autoreactivity to PLP epitopes 
other than those first observed 204-206. The contribution of epitope spreading to the progression 
of autoimmune disease has also been shown in animal models. When mice injected with 
PLP139-151, besides PLP139-151-CD4+ T cell response, they exhibited PLP178-191-specific CD4+ 
T cell reactivity during the first relapse and MBP84-104-CD4+ T cell response during the 
second disease relapse 207,208. The essential role of B cell epitope spreading in EAE has been 
shown in mice immunized with PLP antigen. These mice produced autoantibodies recognized 
not only the immunized antigen but also other myelin epitopes such as MOG and MBP 209.  
Although there have been significant advances in MS research and molecular mimicry and 
epitope spreading are viable hypotheses that could explain how MS is initiated and 
progresses, we are still lacking strong evidence on MS etiology. 
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2 THESIS AIMS 
 
The work in the present thesis aimed to investigate the genetic and immunological regulation 
of autoimmunity in experimental neuroinflammation. Antibodies contribution in multiple 
sclerosis pathogenesis is still under debate. Identification of antibodies genetic regulation and 
elucidation of risk gene variants and underlying molecular mechanisms will give insight in 
disease pathophysiology and may facilitate the development of diagnostic tools and 
therapeutic agents.  
 
Specific scientific goals: 
I. To investigate if anti-MOG and anti-neurofascin antibody response is genetically 
regulated in experimental autoimmune encephalomyelitis and to detect the genomic 
locations and/or genes regulating antibodies response. 
II. To identify if anti-MOG and anti-neurofascin antibodies correlate with 
susceptibility and severity of clinical experimental neuroinflammation. 
III. To delineate pathogenic mechanisms through which C-type lectin-like receptor 
(APLEC) genes, that were linked to anti-MOG antibody response and encode C-
type lectin receptors, modulate experimental autoimmune encephalomyelitis. 
 
 
 

  25 
3 METHODOLOGICAL CONSIDERATIONS 
3.1 GENETIC DISSECTION 
Although the field of human genetics has been rapidly evolving and GWAS have identified 
strong candidate genes in human MS, the use of animal models in detecting risk gene variants 
and elucidating disease molecular pathways is invaluable 210. In traditional reverse genetics 
the focus is to investigate the function of certain candidate genes using genetically engineered 
animals. However, many genes and pathways relevant to disease might not be identified 
using this hypothesis-driven approach. In our laboratory we are using positional cloning i.e. 
forward genetics methodology to identify natural genetic variants, likely to be relevant in 
other species as well, and molecular pathways in an unbiased approach 211. Positional cloning 
is a procedure that detects a gene, responsible for a phenotype, based on its location in the 
genome, using methods such as linkage analysis and association mapping. 
3.1.1 LINKAGE ANALYSIS 
Genetic linkage analysis, based on the observation that genes physically close have the 
tendency to remain linked during meiosis, identifies genes that are inherited together with 
disease 212. Linkage mapping is the statistical method that is used to identify quantitative trait 
loci (QTLs) responsible for a certain trait/phenotype. Polymorphic genetic markers e.g. 
microsatellite (di-, tri- or tetra-nucleotide repeats) or single nucleotide polymorphisms (SNP) 
are utilized to follow certain genomic locations and link them to the trait.  
Linkage analysis is performed in R/qtl package 213. We typically compare non-parametric, 
multiple-QTL and Haley-Knott (HK) model and if they all generate the same results we 
continue with HK. HK which is a simple regression method and the only model that allows 
introduction of covariates and interactions is a powerful tool for QTL mapping in 
experimental crosses between inbred lines 214. In Haley-Knott method, multiple markers are 
analyzed simultaneously and the genotypes in between are predicted based on their 
recombination frequency thus providing good estimates of QTL location. The statistical 
significance of the linkage is expressed by the logarithm of odds (LOD), given as log value 
on the basis of 10, and estimates the likelihood of “QTL linkage” compared to “no QTL 
linkage”. For example, an identified QTL with LOD score of 3 indicates that the odds are 
1,000 that there is a QTL at this location versus that there is no such QTL. The potential 
location of a QTL is defined by the confidence interval (CI) 215. A 95% CI means that there is 
a 0.95 probability that the true location of the QTL is within the CI. 
 26 
Genetic linkage mapping in experimental rat crosses is possible due to the differences at a 
given phenotype/trait i.e. EAE susceptibility and/or antibody response, that different inbred 
rat strains comprise, reflecting the variations in their genetic background. We use populations 
that derive mainly from DA and PVG rat strains, EAE-susceptible and resistant respectively, 
comprising the same MHC genes, thus enabling the detection of non-MHC genomic regions 
responsible for certain phenotypes. 
3.1.2 EXPERIMENTAL CROSSES   
3.1.2.1 Backcross (BC) and advanced intercross line (AIL) 
The rate of recombination events during meiosis determines the size and position of an 
identified QTL and the use of experimental crosses between inbred rat strains increases the 
power of linkage mapping due to the higher recombination events that these populations 
accumulate 216. Linkage mapping in a backcross (BC) population (Figure 8), derived from 
interbreeding F1 hybrids with either one of the parental inbred rat strains and characterized by 
few recombination events, leads to relatively wide QTLs (Figure 10) with high impact on 
trait, though with low number of genetic markers. To narrow down a certain QTL mapped in 
the BC populations, in this thesis we have used advanced intercross line (AIL) in the 10th 
generation (G10). An AIL is obtained by random breeding of two inbred rat strains for 
several generations avoiding brother-sister mating (Figure 8) 217. That increases the 
recombination events and leads to higher resolution mapping identifying QTLs of smaller 
confidence intervals (CI) (Figure 9). However, to get sufficient power to detect a QTL in an 
AIL, higher marker density is required compared to a BC. In Papers I and II, we used two BC 
populations (DABC and PVGBC) deriving from DA and PVG rat strains to genetically map 
anti-MOG and anti-neurofascin antibody response and in Paper I additionally we used a 
DAxPVG G10 AIL to fine map a QTL regulating anti-MOG antibody levels. 
3.1.2.2 Congenic strains 
Congenic rat strains are used to validate if the positionally-cloned (in BC or AIL) phenotype-
regulating QTL has a biological relevance for the trait 218. Congenic lines are established by 
repetitive backcrossing the genomic fragment of interest from one of the parental inbred 
strains (donor) onto the background genome of the other parental strain (recipient) (Figure 8). 
Approximately ten generations of backcrossing are required to minimize the contamination of 
the donor genome outside the genomic fragment of interest. 
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Figure 8. Schematic illustration of population breeding design. Experimental populations can be 
generated by breeding EAE-susceptible DA with EAE-resistant PVG rat strains. Initial F1 generation 
is obtained by crossing the parental strains. The backcross population (BC), permitting rough mapping 
of quantitative trait loci (QTLs), is generated by backcrossing F1 individuals with either parental 
strain. An advanced intercross line (AIL) can be used to narrow down the identified QTLs and is 
produced by random breeding of two inbred rat strains for several generations avoiding brother-sister 
mating. Congenic lines, enabling validation of the linked QTL and functional characterization, are 
obtained by repetitive backcrossing with the selection of the region of interest. 
 
Besides congenic lines’ use in fine genetic dissection and validation of the phenotype, 
congenic strains also represent a powerful tool for mechanistic studies. The functional role of 
the region and/or candidate gene(s) can be further investigated in genetically identical 
congenic rats that are easy to reproduce, and the gene responsible for the phenotype may be 
determined. 
In Papers I and IV, we used congenic rats to validate the Ab response-regulating QTL, 
identified in BCs and AIL, and to further functionally characterize the region and elucidate 
the risk gene(s). The congenic rat strains that we used originated from introgression of alleles 
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of the fragment of interest from the resistant PVG strain onto the genetic background of 
susceptible DA strain. 
 
 
3.1.2.3 Heterogeneous stock (HS) 
The Heterogeneous Stock (HS) is an outbred rat population descended from eight inbred 
founder strains: ACI/N, BN/SsN, BUF/N, F344/N, M520/N, MR/N, WKY/N, WN/N 219 
(Figure 10). These strains, whose genomic sequences are known, were inter-crossed for 62 
generations according to a standard out-breeding rotational schedule to minimize the extent 
of inbreeding, drift and fixation 220. The increased number of recombination events that have 
accumulated over the generations leads to rats with unique genetically random mosaic of the 
founder genomes, attempting to approach the complexity of human population, and increases 
the potential for high-resolution mapping 221 (Figure 9). 
HS provides resolution of genetic mapping exponentially higher compared to an AIL (Figure 
10) and theoretically permits mapping of small-impact regions and QTLs with CI smaller 
than a centimorgan (cM) 222,223. Additionally, the variable MHC regions, that the founder 
strains of HS population carry, enable the identification of both MHC and non-MHC genes. 
In Paper III we used a rat HS to genetically map anti-MOG and anti-neurofascin IgG 
response. 
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3.1.3 ASSOCIATION ANALYSIS 
The population structure of HS rats with different degrees of genetic relatedness requires 
novel statistical approaches 224. Analytical methods and statistical packages, developed 
specifically for mouse HS populations were also used for genome-wide association analysis 
of our rat HS 225,226. Anti-MOG and anti-neurofascin antibody response was analyzed using 
mixed-models, an approach that controls the false positive rate of association by diminishing 
the estimated effect and significance of loci that are predictive of relatedness 227. 
3.2 EAE MODELS 
Studies on this thesis are mainly based on the chronic relapsing-remitting model of EAE 
induced in DA rats by immunization of recombinant MOG1-125 protein with incomplete 
Freund’s adjuvant (IFA). MOG is a unique myelin autoantigen as it induces not only 
encephalitogenic T-cell response but also demyalinating autoantibody response 56. Upon 
MOG immunization, CD4+ T cells are primed in the inguinal LNs by DCs that present 
Figure 10. Schematic 
illustration of rat 
heterogeneous stock 
breeding design. The rat 
heterogeneous stock (HS), 
offering high-resolution gene 
mapping, is an outbred 
population descended from 
eight inbred rat strains 
intercrossed for 62 
generations according to a 
standard outbreeding 
rotational scheme that leads 
to individuals with increased 
number of recombination 
events.  
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MOG and primed T cells migrate through blood circulation into the CNS. T cells get re-
activated by local APCs and enter the parenchyma where soluble mediators secreted by T 
cells, macrophages and microglia, and auto-antibodies secreted by B cells trigger 
demyelination 58,228.  
In the projects of this thesis, we have used two main rat strains, EAE-susceptible DA and 
EAE-resistant PVG strain, populations and congenic strains that have derived from their 
intersections. Within 10-12 days after MOG immunization, DA rats develop clinical signs 
of the disease (Figure 11) characterized by ascending paralysis starting by tail weakness 
and followed by hind leg and subsequently front leg paresis. A common observation prior 
to paresis is loss of body weight. The severity of motor signs is scored by a scale ranging 
from 0 (healthy) to 5 (death) and we assess EAE phenotypes such as incidence, onset, 
duration, maximum and cumulative score and weight loss, that reflect either susceptibily or 
severity of disease. Conversely, PVG rats, sharing the same MHC alleles with DA rats, are 
relatively resistant under the same induction protocol (Figure 11). The differential EAE-
susceptibility of DA and PVG rat strains is due to infuences from non-MHC genes and 
populations originating from DA-PVG intersections facilitate gene identification and their 
functional characterization.  
In one of the studies of this thesis, we have also used the myelin basic protein (MBP)-EAE 
model. EAE induced by active immunization of guinea pig MBP 63-88 peptide with 
complete Freund’s adjuvant (CFA) is acute, monophasic, self-limited disease (Figure 11), 
characterized by extensive T cell infiltration in spinal cord and brain stem with, however, 
very little observable demyelination 229.  
3.3 RATS VERSUS MICE 
Despite the fact that rat had lagged far behind the mouse as a ”genetic model”, 
improvement and development of rat genome resources led to a new era where rat has 
become a powerfool organism for gene discovery 230. The most important advantage of 
using rats in our research is the milder protocol required for EAE induction and the high 
reproducibility of the model compared to the mice that CFA and/or pertussis toxin 231 are 
needed to induce disease and the model is not stable. Other benefits of rats versus mice 
include their bigger size that results in easier animal handling and higher number of 
acquired cells. 
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Figure 11. MOG-EAE and MBP-EAE. Upon immunization with MOG in IFA, EAE-susceptible 
DA rats develop a relapsing-remitting pattern of the disease displaying first clinical signs within 10-12 
days while PVG rats are relatively susceptible (black solid line). On the other hand, upon 
immunization with MBP peptide in CFA, DA rats comprise a short, monophasic disease (dashed 
black line). 
 
3.4 TRANSLATIONAL APPROACH  
Our translational research approach is based on the assumption that there are conserved 
mechanisms between the species. Thus, once forward genetics approach and functional 
studies in rat EAE identify a risk gene and/or the underlying molecular pathway, these can be 
further tested for association in human MS (Figure 9). So far, this approach has been feasible 
in our laboratory and has proven relevant to human disease, identifying gene variants such as 
MHC2TA 232, VAV1 233, CCL2 234, RGMA and IL21R 235 that are important for both EAE and 
MS. When a disease gene is found relevant for MS, it is possible to go back to the 
experimental models to explore further the pathophysiological mechanisms, studies not 
possible in humans, and to develop relevant therapeutics.  
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4 RESULTS AND DISCUSSION 
Autoantibodies role in MS pathophysiology is a field of immense research though antibodies 
relative functional roles and contribution to disease pathogenesis is not clear. Results 
presented in this thesis include the characterization of genetic regulation of anti-MOG and 
anti-neurofascin Abs response and their correlation with disease susceptibility and severity. 
Additionally, the role of APLEC genes, genetically linked to anti-MOG Ab response, and the 
underlying molecular pathways they control during EAE have been dissected and results are 
presented and discussed here. 
4.1 ANTIBODIES IN EAE 
4.1.1 Polygenic regulation of anti-MOG Abs response 
To investigate if anti-MOG Ab levels are genetically regulated, we mapped their response in 
two backcross and one HS rat populations. Genome-wide linkage analysis in 421 DABC and 
471 PVGBC rats and genome-wide association analysis in 1524 HS rats revealed a number of 
QTLs regulating anti-MOG IgG and IgG isotypes. This polygenic and genetically 
heterogeneous regulation of EAE phenotypes, shown in previous studies as well 236-238, 
recapitulates the complex nature of human MS, suggesting that similar genetic mechanisms 
may control susceptibility to develop autoimmune neuroinflammation in several species and 
providing evidence for the relevance and importance of this experimental model to study 
human disease. Additionally, we observed that few of the identified anti-MOG Ab-
controlling QTLs overlap with EAE clinical phenotypes in the BCs 239 and HS, suggesting 
that common molecular pathways might be responsible for EAE and Abs regulation and 
providing evidence for the role of anti-MOG Abs in disease development.   
Likewise, few of the detected QTLs overlap with QTLs identified to regulate other 
inflammatory phenotypes in different experimental models and potentially could be 
controlled by the same gene. For example, Amig3 alleles, the major regulators for anti-MOG 
Abs identified in the BCs, overlap with Oia2, Cia13, Pia7 regulating oil-, type II collagen- 
and pristane-induced arthritis respectively, and Iddm14 linked to glucose levels in T1D 165,240-
242. Interestingly, in the biggest MS GWAS performed in 2011, one third of the identified loci 
overlapped with regions previously associated with other autoimmune diseases such as RA, 
T1D, Crohn’s disease and others 41. During different autoimmune diseases the clinical 
outcome might be different, though certain pathogenic mechanisms might be common, a 
notion supported also by data showing that MS patients may suffer from other autoimmune 
diseases such as T1D and psoriasis 243,244. Importantly, high homology and conserved 
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pathways between species, reflected by studies where molecular mechanisms characterized in 
human disease after being identified in rodents, enables human gene identification through 
also a translational approach.  
4.1.2 Anti-MOG Abs correlate with disease susceptibility and severity 
To investigate if anti-MOG IgG and IgG isotypes associate with disease, we first compared 
Ab levels between rats affected with EAE and healthy rats. In the BC populations, affected 
rats exhibited higher anti-MOG IgG levels compared to healthy population, at both time 
points, onset and late phase of the disease, with the differences being more pronounced 
during onset. Anti-MOG IgG2b and IgG2c response was also increased in the sick rats 
whereas anti-MOG IgG1 levels were higher in the sick versus healthy rats only at onset of 
EAE, and at the late phase healthy rats displayed higher anti-MOG IgG1 levels. In the HS 
population, we observed increased anti-MOG IgG, IgG1 and IgG2b levels in the sick rats 
versus healthy, but no difference in anti-MOG IgG2c titers between the two groups.  
To evaluate if anti-MOG Abs affect EAE severity we studied how Abs correlate with 
clinical EAE phenotypes. Overall in the BC and HS populations, we observed positive 
correlations between anti-MOG IgG, IgG2b and IgG2c and clinical parameters of EAE 
such as maximum and cumulative score. Thus our data strongly supports that the presence 
of anti-MOG Abs associate with disease susceptibility and severity, though we did not 
address whether anti-MOG Abs contribute to disease pathophysiological mechanisms or if 
Abs response is a pure secondary epiphenomenon. Interestingly, the emerging picture is 
that anti-MOG Abs, measured by ELISA, recognizing linear or denatured epitopes cannot 
bind MOG on the cell surface in vivo thereof are not pathogenic 245,246, while conformation-
specific Abs can directly contribute to demyelination 112,247.  
A number of data now implicates MOG as a crucial myelin autoantigen in demyelinated 
disorders including ADEM, optic neuritis and transverse myelitis mainly in children but 
also in adults 132. Although there may be early evidence suggesting anti-MOG 
autoantibody-dependent demyelinated mechanisms, the literature is still lacking in the area 
of the effector mechanisms of anti-MOG Abs in MS autoimmunity. 
4.1.3 Th2 predominance confers protection in EAE 
Interestingly, healthy rats displayed increased ratio of anti-MOG IgG1/IgG2b compared to 
sick rats at all time points after immunization in the BC populations. In addition, APLEC 
congenic strains, that were resistant upon EAE induction, displayed increased levels of anti-
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MOG IgG1 and IgG1/IgG2b ratio compared to DA control rats (Figure 12). Taken together, 
these data imply a protective role of anti-MOG IgG1 versus a pathogenic role of anti-MOG 
IgG2b during EAE development. In rat, IgG1 subtype has been assigned to the IL-4-
producing Th2 phenotype while IgG2b and IgG2c are associated to IFNγ-producing Th1 
dependent response 248,249. Additionally, in rodents IgG1 isotype lacks complement-
activating functions and exhibits lower activatory/inhibitory ratio compared to IgG2b, and 
IgG1 protective role has also been shown in experimental models of SLE 250,251.  
 
Figure 12. Th2 predominance has protective effect. Anti-MOG IgG1/IgG2b ratio is higher in a) 
healthy versus sick rats in DABC and PVGBC at onset and late phase of EAE and b) in APLEC 
congenic rats compared to DA control rats at day 25 and day 40 after MOG immunization. APLEC 
rats remain unaffected while DA rats get sick upon EAE induction. AU, arbitrary units.  
The Th1-Th2 paradigm in EAE and MS has been under extensive research though with 
contradictory data. Adoptive transfer of Th1 cell clones was shown to be sufficient to 
induce EAE, while Th2 clones of the same specificity were not 70,252. Additional studies 
showing that Th2 cells may inhibit encephalitogenic CD4+ T cells underline the protective 
role of Th2 subtypes versus Th1 during disease development 253. Moreover, a variety of 
immune-modulating agents exert their therapeutic properties by shifting the balance 
towards a Th2 phenotype 254-256. On the other hand, Th2 cells have been described in 
Pattern II MS lesions questioning their protective role 257 and Genain et al reported that 
shifting autoimmunity towards Th2 pattern exacerbated EAE in marmosets via the 
production of pathogenic auto-antibodies 258.  
Evidently, shifting the balance away from Th1 towards a Th2 response might not be 
without complications, though our data support the notion that such a Th2 skewed response 
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may confer protection in the context of EAE. Likewise, the differential genetic regulation 
of anti-MOG IgG1 and anti-MOG IgG2b and IgG2c by MHC and non-MHC genes 
respectively in the HS population, suggests that distinct molecular pathways may control 
Th2 and Th1 responses. Nonetheless, especially after the discovery of Th17 cells as key 
players in disease pathogenesis, and considering the enormous plasticity of T-cell 
responses, such a Th2 shift is not a simple option.  
4.1.4 Anti-neurofascin Ab titers associate with disease severity during MOG-EAE 
To investigate the epitope spreading to neurofascin in different EAE models we immunized 
DA rats either with MOG or MBP63-88 peptide. As previously shown, immunization of DA 
rats with MOG leads to T and B cell activation as well as monocyte/macrophage 
recruitment, with extensive demyelination and both immunoglobulin and complement 
deposition in lesions 259,260. In our study the prolonged disease course in MOG-immunized 
rats correlated with the generation of anti-rrNF IgG. On the other hand, the paralysis 
observed in MBP63-88-induced EAE, which is a monophasic self-limited disease, likely 
reflects blood-brain barrier breakdown, cellular infiltration and edema, rather than 
demyelination, 261 and no sizeable epitope spreading to neurofascin could be observed. A 
key, speculative notion here is that an EAE-driving autoantigen such as MOG (but not 
MBP peptide) needs to cause a conspicuous damage to myelin 262 to, in turn, expose the 
immune system to axonal antigens, such as neurofascin, in order to elicit a further 
deleterious autoimmune response which may be involved in disease progression. Such a 
scenario is consistent with the previous observations of a more frequent presence of anti-
neurofascin antibodies in progressive MS 263. How and where the spread of reactivities for 
the B cell compartment occur remains to be established. Our study however, highlights that 
the intermolecular epitope spread can also occur from an antigen exclusively expressed on 
oligodendrocytes (MOG) to an antigen whose expression is shared by oligodendrocytes and 
neurons (neurofascin), which in turn could lead to further epitope spreading to neuronal 
antigens. 
Besides demyelination, MS is characterized by damage to axons/neurons 264. Furthermore, 
in a histopathological study neural damage was always connected to inflammation 265, 
which at some point continues independently from the initial immune attack and can 
contribute to further, and permanent disabilities. It is currently not completely clear what 
leads to axonal injury but epitope spreading to axonal antigens, among other factors, might 
account for the neurodegenerative processes and axonal pathology. Anti-neurofascin 
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antibodies from MS patients have been shown to cause axonal injury in EAE in a 
complement-dependent manner 263,266.  
Interestingly antibodies reacting to neurofascin in our study do cross-react with another 
recently identified target in MS, contactin-2, which is located in the juxtaparanodes 267. If 
responses to these proteins overlap, it might mean that these would constitute hot-spots for 
immune reactivity by both T and B cell reactions to oligodendrocytes and neuronal cells, 
leading to inhibition of nodal function and possibly exacerbation of axonal damage.  
It has been shown in animal studies that epitope spreading is responsible for relapses and 
also leads to increased disease severity and chronicity 203. In our DA backcross population 
anti-neurofascin IgG and IgG2b titers significantly correlated with more severe disease, as 
represented by higher cumulative and maximum score, longer disease duration and higher 
weight loss in rats with anti-neurofascin reactivity compared to rats with no Ab response to 
neurofascin (Figure 13). Thus our data strongly supports that the presence of an anti-
neurofascin response correlates with heightened severity, though if anti-neurofascin Abs 
contribute to axonal pathology or if epitope spreading to neurofascin is a reflection of an 
exacerbated disease is not clear. 
 
Figure 13. Anti-neurofascin antibodies correlate with EAE severity. DA backcross rats with 
anti-neurofascin Abs (anti-rrNF IgG (+)) are more severely sick compared to rats without anti-
neurofascin reactivity (anti-rrNF IgG (-)) as indicated by higher maximum (MAX) and cumulative 
(SUM) EAE score, longer duration of disease (DUR), earlier onset of the disease (ONS) and lower 
weight loss (WL0).  
4.1.5 Anti-neurofascin Abs are genetically regulated 
In our genome-wide linkage analysis, we identified a QTL on chromosome 3 that is linked 
to anti-neurofascin IgG2b isotype-specific response in 174 female DA backcross rats, 
suggesting that anti-neurofascin reactivity is under genetic regulation. Interestingly, this 
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locus on chromosome 3 overlaps with QTLs that have been detected in different crosses 
such as DABC, PVGBC, AIL and HS, that regulate various EAE phenotypes such as EAE 
severity (in the DABC, PVGBC and AIL G10) and anti-MOG IgG (in the DABC), IgG2b 
(in the AIL G10) and IgG2c (in the PVGBC and HS) response. Our genome-wide 
association analysis in the HS population identified only MHC regions, and specifically 
MHC classes III, II and Ia, on chromosome 20, to control anti-neurofascin IgG response, 
implying that the influence of non-MHC alleles may be diminished when MHC regions 
exert an effect. These MHC loci were also linked to anti-MOG IgG and IgG1 response in 
the HS population. Taken together, these data imply that genetic polymorphisms in the loci 
identified on chromosomes 3 and 20, may influence general, rather than neurofascin-
specific auto-antibody response and/or other autoimmune mechanisms that regulate EAE 
severity. 
Our findings are interesting in view of the current development in MS genetics. So far, only 
risk loci controlling incidence of MS have been described, likely due to poor methods to 
measure MS severity on a large scale, as well as lack of appropriate intermediate sub-
phenotypes. The data shown here encourages further attempts in MS, on a genome-wide 
level to study genetics in relation to severity and to sub-phenotypes. 
4.2 GENETIC MAPPING IN HETEROGENEOUS STOCK  
4.2.1 HS identified both MHC and non-MHC regions and pinpointed candidate 
genes 
We also used a unique population, the rat HS, that offered the opportunity to map Abs 
response in rats with mixed MHC types, not possible in any other population we used in 
this thesis as they carry the same MHC alleles. Thus HS population enabled genetic 
dissection of both MHC and non-MHC regions-regulating Abs response. HS rats, that have 
accumulated high number of recombination events over the generations, offered the 
potential of high-resolution mapping compared to other populations used, and allowed us to 
pinpoint candidate risk genes.  
Among the five regions within the MHC locus associated to anti-MOG Abs response, MHC 
class II and Ia alleles were the major regulators and MHC class II displayed the strongest 
association. That is consistent with findings from human case-control cohorts where MHC 
II alleles exert the highest impact on disease. Identified MHC class II QTL contains 35 
genes, highly conserved among mammals 268, including the ones encoding the beta chain of 
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RT1-Db1, whose human homologs, HLA DRB1 and DRB5 are the major risk genes for 
MS. Additionally, MHC II QTL was previously associated to CD4:CD8 T cell ratio in 
blood from naïve HS rats 269. Tap-2 alleles were identified to be responsible for the T cell 
effect and Tap-2, which is at the border of the identified MHC II QTL, may also influence 
Abs response.  
MHC class Ib QTL that mainly controls anti-MOG IgG1 thus Th2-associated response, 
consists of a single gene, RT1-CE10, that encodes for the H2 class I histocompatibility 
antigen alpha chain, involved in antigen processing and presentation via MHC class I. We 
identified a SNP in RT1-CE10 that results in an amino acid change, from arginine to lysine, 
that in some contexts may be harmful 270.  
Non-MHC regions were identified to control mainly anti-MOG IgG2c and IgG2b, related to 
Th1-driven response. Among the genes in the associated non-MHC QTLs we pinpointed 
IgKc on chromosome 4 and Ccr7 on chromosome 10 as candidate genes controlling anti-
MOG Abs response. IgKc encodes the constant domain of kappa light chains of antibodies 
and in humans IGKC has been associated with different types of cancer 271,272. Ccr7 
encodes for CCR7 chemokine receptor. CCR7+ myeloid cells have been detected in MS 
brain lesions and CSF 273,274, and CCR7 expression has been shown to be up-regulated in 
the CNS of EAE animals 275,276. Though, how candidate genes influence Abs response 
and/or EAE pathogenesis remains to be investigated.  
4.3 C-TYPE LECTIN RECEPTORS IN EAE 
4.3.1 APLEC (antigen-presenting lectin-like) gene cluster was the major regulator of 
anti-MOG Ab response 
Although anti-MOG Ab response was controlled by several loci in the BC populations, 
Amig3 alleles were the major regulators in both BCs and both at onset and late phase of 
EAE. Though Amig3 locus spanned a region of several Mb harboring several genes. To 
fine-map Amig3 QTL, we used an AIL in the 10th generation. The AIL analysis narrowed-
down Amig3 into a region of approximately 0.5 Mb with LOD score of 38. In AIL, Amig3 
was linked to anti-MOG IgG and IgG1 and PVG alleles predisposed for higher Ab levels 
(Figure 14).  
To validate the QTL’s effect identified in BCs and AIL populations we used APLEC 
congenic strain. APLEC congenic originates from introgression of resistant PVG Amig3 
alleles into the DA susceptible background. Antigen-presenting lectin-like (APLEC) locus 
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harbors a cluster of genes (Dcir4, Dcir3, Dcir2, Dcir1, Dcar1, Mcl and Mincle) encoding C-
type lectin receptors (CLRs) that are expressed mainly in APCs and are important innate 
sensors. Anti-MOG IgG1 and ratio IgG1/IgG2b was increased in APLEC versus DA control 
rats both at onset and late phase of disease and APLEC rats were drastically protected upon 
MOG immunization implying common molecular pathways.  
 
Figure 14. Mapping in AIL G10 narrowed down Amig3 locus and identified C-type lectin 
genes as the major regulators of anti-MOG Ab response. a) Amig3 locus was fine-mapped into a 
0.5 Mb region with LOD score of 38 and was linked to anti-MOG IgG and IgG1 response. b) PVG 
alleles predisposed for higher Ab levels. c) APLEC locus harbors a cluster of C-type lectin genes. 
DD, DA/DA; DP, DA/PVG; PP, PVG/PVG. 
4.3.2 APLEC genes involvement in EAE 
To elucidate how resistant PVG alleles in the APLEC locus confer protection upon MOG 
immunization we analyzed cell numbers in the peripheral compartment i.e. the inguinal 
lymph nodes, where priming of the disease takes place, seven days p.i.. We observed 
increased B cell numbers in the APLEC compared to DA control rats, while T cells and 
TNF-producing T cells were decreased in the APLEC congenic strain. Anti-MOG IgG1 
titers and anti-MOG IgG1/IgG2b ratio were also increased in the sera of the congenic rats.  
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The impact of APLEC alleles on the B cell compartment has previously been shown in an 
arthritis model using different inbred rat strains 277. Moreover, Guo et al showed that 
APLEC congenic rats displayed higher serum IgG1 Ab titers against CII in experimental 
arthritis 278. In the same study, they showed that PVG alleles in the APLEC locus decreased 
IL-17, IL-1β (associated to Th17) and IFNγ (associated to Th1 response) mRNA levels in 
the LNs 10 days after CIA. A plausible hypothesis in our model (Figure 15), is that upon 
MOG immunization PVG alleles in the APLEC locus may modulate the expression of 
molecules such as cytokines involved in T cell differentiation and skew T cells towards a 
Th2 response as indicated by increased anti-MOG IgG1 and IgG1/IgG2b ratio, thus 
conferring protection. Since IgG2b isotype but not IgG1 activate the complement system 
279, IgG1 may have less encephalitogenic properties thus decelerating EAE development. 
The diminished Th1/Th17 polarization is also indicated by the decreased levels of IFNγ, 
IL-1β and IL-17 cytokines 278 and TNF-producing T cells in the APLEC congenic 
compared to DA rats. Mitsdoerffer et al have shown that IL-17 cytokine can induce little 
IgG2b production but no IgG1 280. Although anti-MOG IgG2b titers did not significantly 
differ between DA and APLEC congenic rats, significantly lower ratio of anti-MOG 
IgG1/IgG2b and increased IL-17 in the DA rats implies that besides IFNγ, IL-17 may also 
promote the shift towards IgG2b isotype (Figure 15). 
 
Figure 15. Proposed model of PVG alleles in APLEC region conferring protection during EAE. 
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CLRs have been implicated in a number of autoimmune diseases (Table 2, page 20), though 
the ligands for most of the receptors and how they exactly modulate autoimmune 
phenotypes are not clear to date. In our model, it is hard to speculate which of the APLEC 
genes is/are the risk gene/s. The Dcir2 and Dcir1 effect on Abs response has been shown in 
experiments using Dcir2 KO and Dcir1 KO that were more severely sick during EAE and 
CIA respectively, and displayed higher anti-MOG and anti-CII Ab levels compared to WT 
162,163. Hence, Dcir2 and Dcir1 serve as attractive candidates but without excluding the rest 
of the APLEC genes as responsible for the underlying effect during EAE. On the other 
hand, Mcl and Mincle have recently drawn a lot of attention due to their recognition as 
sensors of TDM, a molecule of the Mycobacterium Tuberculosis cell wall, and their 
implication in a number of diseases such as EAE, TBI and cerebral ischemia.  
mRNA expression levels of APLEC genes in in vitro generated bone marrow (BM) APCs 
revealed more drastic differences in Mcl and Mincle expression between DA and APLEC 
strains (data not shown). Luckily, in our laboratory there is another congenic strain 
(R11R6) available, harboring PVG alleles in only three of the APLEC genes (Dcar1, Mcl 
and Mincle), on the susceptible DA background. R11R6 congenic rats were drastically 
protected upon MOG immunization, designating any of Dcar1, Mcl and/or Mincle as risk 
gene/s. Therefore, we decided to focus our further studies on how genes in the R11R6 
congenic strain modulate EAE. Studies on R11R6, harboring three instead of the seven 
genes in the APLEC congenic, may easier identify the risk gene(s) and the underlying 
molecular pathways that lead to protection during EAE, though we do not imply that Dcir 
genes have no effect in disease development.   
4.3.3 C-type lectin receptors (Mcl and Mincle) modulate EAE 
In the last study of the thesis we utilize R11R6 congenic strain to study the role of Mcl and 
Mincle receptors during EAE development. Besides Mcl and Mincle genes, R11R6 
congenic harbors Dcar1 as well. There is no known natural ligand for Dcar1 to date, thus it 
is not easy to study the type of response it would induce in our system. Importantly, besides 
TDM binding, Mincle has also been recognized to sense SAP130 177, released from dead 
cells, thus acting as DAMP, suggesting a prominent role of the receptor in host immune 
homeostasis. Furthermore, we observed more striking differences in Mcl and Mincle than 
Dcar1 mRNA expression between R11R6 congenic and DA control rats. Therefore, we 
decided to focus our studies on how Mcl and Mincle may modulate EAE, though we do not 
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ignore the possibility that Dcar1 may also have an effect in disease development and we are 
planning to test Dcar1 effect as well. 
We observed lower Mcl and Mincle mRNA expression in a number of myeloid cells such as 
in vitro G4-bone marrow dendritic cells (BMDC), generated with GM-CSF/IL-4 
resembling monocytes (MO), (MO)-derived inflammatory DCs (MO-DCs), BM 
macrophages (BMMa), generated with M-CSF, and in brain-derived microglia in the 
R11R6 compared to DA rats. Additionally, R11R6 blood MOs and granulocytes displayed 
decreased Mcl and Mincle expression compared to DA control rats. Furthermore, upon 
ligand (TDM or its synthetic analog trehalose dibehenate (TDB)) stimulation, myeloid cells 
from the two strains exhibited differential response in a number of cytokines, such as IL-6, 
IL-23, IL-12/23p40 (implicated in Th17 pathway), TNF and iNOs, and chemokines such as 
CXCL1, CCL2 and CCL3 (involved in neutrophil, monocyte and macrophage 
chemoattraction respectively). In vitro studies revealed that supernatant from R11R6 
myeloid cells promoted T cells to produce more IL-10 and less IFNγ and IL-17. Upon 
MOG protein immunization without mycobacteria, R11R6 rats were drastically protected 
and displayed lower demyelination and inflammatory cell infiltration in the CNS compared 
to DA rats. In a kinetics experiment, we did not observe any qualitative differences in the 
inguinal LNs, draining the site of injection, at different time points after MOG 
immunization between the two strains. At day 13 during EAE, the CNS of R11R6 rats 
displayed diminished numbers of infiltrating cells such as lymphocytes, Ma/MO and 
granulocytes and infiltrating cells were also less activated. Additionally, CNS infiltrating T 
cells in R11R6 congenic rats had reduced capacity to polarize into Th17 cells, shown by 
lower levels of IL-17 cytokine, while Th1 was not affected, indicated by similar IFNγ 
response between the two strains (Figure 16).  
We demonstrate here that Mcl and Mincle signaling skew T cell development towards Th17 
subsets, whose prominent role during EAE has already been recognized. The diminished 
IL-6 and IL-23 mRNA expression observed in R11R6 versus DA myeloid cells (Figure 16) 
further support this notion, as Th-17 cells and IL-17 production can be amplified by the 
presence of IL-6 and IL-23 281.  
 44 
 
Figure 16. C-type lectin receptors skew T cells towards Th17 differentiation. a) R11R6 
congenic rats displayed diminished CNS infiltrating IL-17-producing lymphocytes compared to DA 
rats while IFNγ production was similar 13 days p.i.. b) mRNA expression of IL-6, IL-23 and 
IL12/p40, cytokines associated to Th17 lineage, was reduced in in vitro generated myeloid cells 
upon TDM and/or TDB stimulation in R11R6 compared to DA rats. G4-BMCD, Bone marrow 
dendritic cells generated with GM-CSF/IL-4; BMMa, Bone marrow macrophages. 
Interestingly, we did not observe any qualitative differences in the inguinal LNs, where T 
cell priming occurs, indicating that C-type lectin receptors (CLRs) do not influence initial T 
cell activation in the peripheral compartment during EAE, in our system. We could detect 
SAP130 in the CSF of DA rats both in naïve state and during EAE. Thus, we hypothesize 
(Figure 17) that upon MOG immunization, perivascular macrophages and meningeal 
microglia, playing essential role in primary reactivation of auto-reactive T cells in the CNS 
282, may bind SAP130 through Mincle and subsequently re-activate T cells. Although we 
observed diminished Mcl and Mincle mRNA expression in in vitro generated myeloid cells 
of R11R6 congenics, we did not determine the exact cell-type that mediates Mcl and 
Mincle signaling. We also observed reduced numbers of CNS infiltrating cells and 
diminished levels of TNF and CXCL1, CCL2 and CCL3, important for cell infiltration and 
attraction into the CNS, in the R11R6 rats. It has been shown that signaling through Mincle 
results in increased TNF, CXCL1 and CXCL2 185. Decreased production of TNF and IL-17 
observed in R11R6 myeloid cells may account for the diminished levels of chemokines 
resulting in lower number of infiltrating cells into the brain 177,283,284.  
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IL-17 will further induce endothelial cells to produce G-CSF and IL-6 and these cytokines 
will in turn induce bone marrow to produce neutrophils, a process known as emergency 
granulopoiesis 285,286. R11R6 congenic rats displayed diminished granulocyte numbers both 
in the CNS and in the peripheral blood (data not shown) 13 days p.i. compared to DA rats, 
suggesting that R11R6 may display lower emergency granulopoiesis.   
Importantly, knockdown of Mcl plus Mincle receptors resulted in slightly lower EAE 
severity in the DA strain in a pilot study. Although we did not observe significant 
differences between DA rats treated with Mcl plus Mincle and scramble siRNA, and the 
conditions of the experiment need to be optimized, the results were promising.  
Albeit Dcar1 has a nonsense mutation in the DA rat 287 and Dcar1 receptor signals through 
ITAM binding, implying activating function in the R11R6 congenic, it may very well have 
regulatory functions as well. For example, BDCA2, the human homologous to Dcar1 
receptor, has been shown to play an inhibitory role in the homeostatic regulation of 
plasmacytoid DCs (pDCs) and type I IFNs production during SLE development 168 and 
pDC secretion of TNF-related apoptosis-inducing ligand (TRAIL) is inhibited by BDCA 
signaling 288. Thus, Dcar1 may very well confer protection in R11R6 congenic rats by 
inhibiting autoimmune response, while DA rats may be susceptible due to the nonfunctional 
mutation they carry in Dcar1. Though, the limited available tools to study Dcar1 prompted 
us to focus on Mcl and Mincle for the time being but with the intention to investigate 
potential involvement of Dcar1 in EAE pathogenesis in our future studies.  
Exactly how CLRs are involved in MS pathogenesis is not clear and needs further 
investigation. Molecular mimicry is one of the proposed mechanisms for disease initiation. 
Upon CLR binding of microbial antigens, cross-reacting with endogenous danger 
molecules such as SAP130, may activate DCs and prime Th17 cells that in turn become 
encephalitogenic after their reactivation within the CNS by DCs that recognize cross-
reacting alarm signals (Figure 17). 
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Figure 17. Proposed hypothesis on how C-type lectin receptors may confer risk in EAE/MS. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
MS is a complex disease with increased heterogeneity in regards to clinical 
symptoms/signs/course, immunopathology and response to disease modifying 
treatments. Complex genetic factors interacting with environmental triggers and 
epigenetic changes may account for disease heterogeneity, leading to a number of 
pathophysiological mechanisms and sub-phenotypes. To date MS cause has not 
been elucidated and the available therapeutics do not substantially halt the disease, 
but they rather limit its impact by reducing disease relapses and provide symptoms’ 
relief. MS is a devastating disease, affecting mainly young adults, decreasing 
quality of life and life expectancy. Thus, it seems imperative to elucidate gene 
variants and underlying molecular pathways conferring risk for disease 
development. MS is a disease difficult to study, due to limited access and 
availability of the target organ, the CNS. Thus, EAE is a great tool facilitating 
investigation of disease genetic and molecular mechanisms and validation of 
therapeutic compounds.  
5.1 POSITIONAL CLONING  
In this thesis following an unbiased approach we utilized EAE to study the genetic 
control and involvement of anti-MOG and anti-neurofascin Abs in disease. We 
determined that anti-MOG Abs are under polygenic control and APLEC genes are 
the major regulators of their response. For our genetic dissection, we made use of a 
number of different rat populations, that enabled us to identify both MHC and non-
MHC alleles. BC populations were used for the initial genetic mapping of immune 
phenotypes, identifying broad QTLs harboring many genes. An AIL G10 population 
fine-mapped anti-MOG Abs-regulating loci, and congenic strains, consisting of 
PVG APLEC alleles in the susceptible DA background, were utilized to further 
validate identified Ab-controlling QTL and enabled functional studies to investigate 
risk gene(s) and the underlying molecular mechanisms. Thus, we concluded that 
forward genetics approach (Figure 18), enabling the identification of naturally 
occurring polymorphisms, is a powerful tool for genetic dissection of phenotypes 
and detection of genes and molecular pathways relevant to disease Although in this 
thesis we did not reach to the point to test our findings on human material, which is 
 48 
planned for future studies, there are examples that discoveries made in experimental 
models have been successfully translated to human disease. Among others, 
MHC2TA polymorphism associated to RA, MS and myocardial infarction was 
initially identified in rodents 232. Nonetheless not all genetic findings can be directly 
translated to humans, although molecular pathways controlled by identified genes 
may operate similarly between species. The paradigm of the positional cloning of 
Ncf1 in experimental arthritis 289 that led to the investigation of a novel pathway in 
humans and the discovery of NCF4 association to RA 290 reflects this notion. 
 
 
Figure 18. Summary of our translational approach. Quantitative trait loci (QTLs)-regulating 
disease phenotypes (e.g. Abs response) were initially identified in experimental rat populations 
(e.g. backcrosses) and subsequently fine-mapped in advanced intercross lines. Congenic lines 
were used to validate QTLs effect and functionally characterize the region and pinpoint risk 
genes. Candidate genes or underlying molecular pathways can be further tested for association 
in human cohorts.  
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In this thesis we also made use of a unique population, the rat HS that attempts to resemble 
a human outbred population. The rat HS is a powerful genetic mapping tool that enabled 
detection of QTLs spanning narrow regions and comprising fewer genes than those 
identified in other populations used. Additionally, genome-wide association mapping in HS 
dissected both MHC and non-MHC regions and pinpointed risk genes. MHC dissection in 
HS rats, not possible in any other populations used in this thesis, is particularly important, 
as MHC alleles exert the highest impact on MS susceptibility and unraveling molecular 
pathways underlying MHC control may give insight in disease mechanisms. 
HS rats have the advantage of the known genomic sequences of their founder strains. Thus, 
SNP associations can be traced back to their original strains and that enables the 
development of congenic rat strains to further validate SNPs effect. A number of other 
immune phenotypes of HS rats such as pro- and anti-inflammatory cytokines, and tissues 
and organs such as spleen and spinal cord, that we have available, will facilitate further 
investigation of the identified regions and will be used for follow-up studies of defined risk 
genes. Additionally, identified candidate genes may be tested for genetic association in 
large MS case-control cohorts. 
5.2 ANTIBODIES IN MULTIPLE SCLEROSIS 
Anti-MOG Abs correlated with disease susceptibility and severity. Anti-neurofascin Abs 
correlated also with disease severity and their response was genetically regulated, though 
whether the identified genomic regions are specific for anti-neurofascin response or they 
control general antibody responses is not clear. The finding that anti-neurofascin Abs 
response is genetically regulated is particularly important in the view of current 
development of MS genetics, encouraging further genetic studies in relation to severity and 
intermediate sub-phenotypes.  Autoantibodies have been implicated in MS pathogenesis for 
many years. While there is convincing evidence for the clinical significance of anti-
aquaporin-4 Abs in neuromyelitis optica, anti-acetylcholine receptor Abs in myasthenia 
gravis and anti-citrulline Abs in RA, autoantibodies contribution to MS pathogenesis is still 
under debate. Identification of autoantibodies genetic regulation and underlying molecular 
pathways will facilitate answering the question whether autoantibodies are essential in 
disease pathogenesis or whether they reflect an ongoing activation of the B cell 
compartment as APCs that might mediate further activation and antigen spreading. And if 
eventually autoantibodies are shown to be non-pathogenic, they can still serve as 
biomarkers for diagnosis, prognosis, treatment responses and/or disease sub-categorization.  
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We identified a protective effect of Th2-related anti-MOG IgG1 isotype compared to Th1-
driven isotypes IgG2b and IgG2c. One way to investigate their relative importance in vivo 
would be to inject EAE rats with affinity purified anti-MOG IgG1 or IgG2b Abs and 
determine if they protect or promote disease respectively. Though this procedure of affinity 
purification of specific Abs (anti-MOG), certain subclass (IgG) and certain isotypes (IgG1 
and IgG2b) is quite laborious requiring multiple purification steps and thus a substantial 
amount of serum.  
Our findings of anti-MOG IgG1/IgG2b protective role in EAE suggest that shifting the 
balance towards Th2 response may be beneficial during disease. For example, GA, a first 
line treatment for MS has been shown to exert its therapeutic efficacy by Th2-polarized 
immune response as well 291. Admittedly, shifting the balance towards Th2 predominance 
might not be without side effects as Th2 immune response is associated also to 
hypersensitivity reactions.  
5.3 C-TYPE LECTIN RECEPTORS IN MULTIPLE SCLEROSIS 
We have also tried to pinpoint the risk gene(s) among the ones in APLEC gene locus and 
the underlying molecular mechanisms contributing to disease during EAE. An older 
genome scan in MS affected families revealed a peak, although not replicated in future 
studies, which covered APLEC locus, implicating APLEC genes in disease pathogenesis 292. 
Additionally, APLEC alleles have also been associated to human RA 293 and were linked to 
experimental models of arthritis and T1D 242. Taken together, these data indicate that one or 
more of the CLRs encoded by APLEC genes may be involved in the pathogenesis of several 
autoimmune diseases and suggest that conserved mechanisms apply between species. 
Furthermore, these data provide evidence for the usefulness of positional cloning on 
experimental animal models to identify genes and pathways relevant to human disease.   
CLRs that function as PRRs are important components in host defense against pathogens. 
The recognition of SAP130, released by damaged cells, as Mincle endogenous ligand, 
pinpointed the potential role of CLRs in host immune homeostasis. According to the danger 
model proposed by Pauly Matzinger, some autoimmune diseases may be caused by 
abnormal physiological death and defective clearance processes, or by environmental 
pathogens or toxins that cause cellular stress or death 294. In concordance, exacerbated 
inflammatory responses to dying cells have been associated to autoimmune diseases such as 
SLE, and HMGB1, a non-histone nuclear protein, has been recognized as a trigger of sterile 
inflammation in autoimmune diseases 295. SAP130 may also turn out to provoke 
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autoimmune responses through CLR binding and currently the type of inflammatory 
response that SAP130 induces in APCs and APC:T cell co-cultures is under investigation in 
our laboratory. Additionally, Mass spectrometry analysis of CSF of MS patients may reveal 
SAP130, implying its potential role as alarm signal in disease pathogenesis.  
CLRs have been implicated in a number of autoimmune diseases. Evidently the role of 
CLRs can be both pathogenic and inhibitory regardless of their association with ITIM or 
ITAM, thus it is not easy to determine the risk gene(s) in our model. Therefore, we focused 
on the role of Mcl and Mincle during EAE, though how APLEC variants confer risk is not 
entirely clear. BM chimera experiments will facilitate answering the question of whether 
blood or CNS resident myeloid cells are the critical components on Mcl and Mincle 
signaling. Conditional deletion of Mcl and Mincle on certain immune cell types will also 
contribute to the elucidation of cellular mediators of Mcl and Mincle receptors and will 
pinpoint either of the genes (if not both) as candidates. In our laboratory we have available 
MclFlox/Flox and MincleFlox/Flox mice and a number of mouse Cre-LoxP lines expressing 
recombinase Cre in certain cell types such as immune cells (Rosa26-Cre), microglia 
(Cx3cr1-Cre) and myeloid cells (LysM-Cre). Additionally, R11R6 congenic strain and 
conditional knockdown mice will be tested in other experimental models, such as TBI and 
stroke, and that may provide further evidence for a general implication of APLEC variants 
in CNS disorders and may facilitate unraveling molecular mechanisms.  
Whether both Mcl and Mincle or only one of the receptors account for the effect during 
EAE is not clear. Findings showing that Mcl positively facilitates Mincle expression 182 and 
signaling and that co-expression of Mcl and Mincle leads to a dramatic increase of Mincle 
phagocytic activity 180 imply that receptors interact in a synergistic manner and maybe both 
are essential to confer risk in our system. 
Upon ligand binding Mcl and Mincle recruit Syk that induces Bcl10-Malt1-Card9 signaling 
cascade resulting in NF-κB activation and inflammatory cytokines induction. MALT1 and 
BCL10 were found to be strongly associated to human MS in GWAS 41,193. A search for 
MS associated SNPs in either MCL or MINCLE or in any of the signaling cascade 
molecules might provide further hints for the implication of the receptors or their 
downstream targets in disease pathogenesis. Additionally, we have access to human 
peripheral blood mononuclear cells (PBMCs) and the corresponding  genotypes from 
healthy donors and MS patients. CyTOF (Cytometry by Time-Of-Flight) analysis, a new 
technology providing multiparameter single-cell analysis, of PBMCs upon TDM or TDB 
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stimulation may reveal differential response of individuals with certain genotypes in 
particular SNPs thus providing clues for predisposing genes in Mcl/Mincle pathway and 
may offer valuable insight into pathophysiological mechanisms.  
Taken together, CLRs are essential contributors in host immune homeostatic control and 
may play prominent role in development of autoimmunity. Thus, similar to TLR agonists 
and antagonists that have already been approved or are currently under clinical trials for the 
treatment of autoimmune diseases such as SLE, RA and MS 296,297 CLRs may also 
represent candidate targets for the designing of new therapeutic agents. Likewise, SAP130 
may also serve as a potential therapeutic target, as has been shown for HMGB1 
neutralization by mAbs that leads to down-regulation of inflammatory cascade in a number 
of experimental models including EAE 298,299.  
In conclusion, in this thesis genetic and immunological studies were combined to pinpoint 
risk genes and unravel disease pathogenic mechanisms. Our findings enhance MS 
knowledge and may facilitate the development of effective prognostic, diagnostic or 
therapeutic tools/agents (Figure 19).  
 
Figure 19. Summary of thesis findings and their potential implication in design diagnostic and 
prognostic tools or therapeutic agents for multiple sclerosis.  
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